CHICAGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Accretive Health, Inc. (the “Company”)  (OTC Pink:ACHI), a leading provider of revenue cycle services and physician advisory services to healthcare providers, today announced results for the quarter ended June 30, 2016.

Second Quarter 2016 Results:

• GAAP  net services revenue of $8.7 million, compared to $22.1 million for the second quarter of 2015
  
  
• GAAP  net loss of $40.8 million, compared to a net loss of $26.3 million for the second quarter of 2015
  
  
• Non-GAAP gross cash generated from customer contracting activities of $38.3 million, compared to $47.2 million for the second quarter of 2015
  
  
• Non-GAAP net cash generated from customer contracting activities of negative $17.4 million, compared to negative $6.6 million for the second quarter of 2015

“In the second quarter, we made progress in aligning our cost structure to our current business needs while investing in our organizational capabilities to drive future growth. We are firmly committed to making the right investments to enable the company to succeed over the long term. I am pleased with the pace of execution against our near term objectives and our clarity of strategic focus going forward,” said Joe Flanagan, President and Chief Executive Officer of Accretive Health.

“The actions we took in the second quarter are an important step in placing us on a path back to profitability.  We now have a more efficient company cost structure which provides us with better operating leverage as we grow,” added Chris Ricaurte, Chief Financial Officer and Treasurer.

Conference Call and Webcast Details
Accretive Health’s management team will host a conference call today at 5:00 p.m. Eastern Time to discuss the results and business outlook. To participate, please dial 877-880-5884 (631-601-2894 outside the U.S. and Canada) using conference code number 50457674. A live webcast and replay of the call will be available at the Investor Relations section of the Company’s web site at www.accretivehealth.com.

Non-GAAP Financial Measures
In order to provide a more comprehensive understanding of the information used by Accretive Health’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial measures, which are included in this press release. These include gross and net cash generated from customer contracting activities and adjusted EBITDA. Our Board and management team use these non-GAAP measures as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations; and (ii) a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation programs for employees.

Gross cash generated from customer contracting activities is defined as GAAP net services revenue, plus the change in deferred customer billings. Accordingly, gross cash generated from customer contracting activities is the sum of (i) invoiced or accrued net operating fees, (ii) cash collections on incentive fees and (iii) other services fees.  Net cash generated from customer contracting activities reflects non-GAAP adjusted EBITDA and the change in deferred customer billings.

Adjusted EBITDA is defined as net income before net interest income (expense), income tax provision, depreciation and amortization expense, share-based compensation expense, reorganization-related expense and certain other items. The use of adjusted EBITDA to measure operating and financial performance is limited by our revenue recognition criteria, pursuant to which GAAP net services revenue is recognized at the end of a contract or other contractual agreement event.  Adjusted EBITDA does not adequately match corresponding cash flows from customer contracting activities.  As a result, the Company uses gross cash and net cash generated from customer contracting activities to better compare cash flows to operating performance.

Deferred customer billings include the portion of both (i) invoiced or accrued net operating fees and (ii) cash collections of incentive fees, in each case, that have not met our revenue recognition criteria. Deferred customer billings are included in the detail of our customer liabilities and customer liabilities – related party balance in the condensed consolidated balance sheets available in the Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2016.

Table 4 presents a reconciliation of GAAP revenue to gross cash generated from customer contracting activities,  and Table 5 presents a reconciliation of GAAP net income (loss), the most comparable GAAP measure, to adjusted EBITDA and net cash generated from customer contracting activities, in each case, for each of the periods indicated.  These adjusted measures are non-GAAP and should be considered in addition to, but not as a substitute for, the information prepared in accordance with GAAP.

Safe Harbor

This press release contains forward-looking statements, and in particular, any statements about future growth, plans and performance are forward-looking statements. All forward-looking statements contained in this press release involve risks and uncertainties. The Company’s actual results and outcomes could differ materially from those anticipated in these forward-looking statements as a result of various factors, including the factors set forth under the heading “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 10, 2016. The words “strive,” “objective,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “vision,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company has based these forward-looking statements on its current expectations and projections about future events. Although the Company believes that the expectations underlying any of its forward-looking statements are reasonable, these expectations may prove to be incorrect and all of these statements are subject to risks and uncertainties. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections, or expectations prove incorrect, actual results, performance, financial condition, or events may vary materially and adversely from those anticipated, estimated, or expected.

All forward-looking statements included in this press release are expressly qualified in their entirety by these cautionary statements. The Company cautions readers not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the uncertainties and factors described above, as well as others that the Company may consider immaterial or does not anticipate at this time. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, the Company does not know whether its expectations may prove correct. The Company’s expectations reflected in its forward-looking statements can be affected by inaccurate assumptions it might make or by known or unknown uncertainties and factors, including those described above. The risks and uncertainties described above are not exclusive, and further information concerning the Company and its business, including factors that potentially could materially affect its financial results or condition or relationships with customers and potential customers, may emerge from time to time. The Company assumes no, and it specifically disclaims any, obligation to update, amend, or clarify forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. The Company advises investors, however, to consult any further disclosures it makes on related subjects in our periodic reports that it files with or furnishes to the SEC.

About Accretive Health

Accretive Health is a leading provider of revenue cycle services and physician advisory services to healthcare providers. Accretive Health’s mission is to help healthcare providers strengthen their financial stability so they can deliver better care at a more affordable cost to the communities they serve, increasing healthcare access for all. Accretive Health’s distinctive operating model includes people, processes, and sophisticated integrated technology and analytics that help customers realize sustainable improvements in their operating margins and improve the satisfaction of their patients, physicians, and staff. Accretive Health’s customers typically are multi-hospital systems, including faith-based or community healthcare systems, academic medical centers and independent ambulatory clinics, and their affiliated physician practice groups.

Table 1
Accretive Health, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
	June 30,  2016				December 31,  2015
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	221,673			$	103,497
Short-term investments	—				1,023
Accounts receivable, net	6,575				10,194
Prepaid income taxes	534				1,102
Other current assets	13,392				10,924
Total current assets	242,174				126,740
Property, equipment and software, net	30,447				27,217
Non-current deferred tax assets	213,908				300,825
Restricted cash equivalents	1,500				1,500
Other assets	4,902				4,007
Total assets	$	492,931			$	460,289
Liabilities and stockholders' equity (deficit)
Current liabilities:
Accounts payable	$	3,735			$	5,306
Current portion of customer liabilities	144,619				202,516
Current portion of customer liabilities - related party	141,089				—
Accrued compensation and benefits	16,273				9,062
Other accrued expenses	20,434				15,743
Total current liabilities	326,150				232,627
Non-current portion of customer liabilities	24,667				432,477
Non-current portion of customer liabilities - related party	26,554					—
Other non-current liabilities	9,810				8,498
Total liabilities	387,181				673,602
8.00% Series A convertible preferred stock: par value $0.01 per share, 200,000 shares issued and outstanding as of June 30, 2016; no shares authorized or issued as of December 31, 2015 (aggregate liquidation value of $206,040 as of June 30, 2016)	163,269				—
Stockholders' equity (deficit):
Common stock, $0.01 par value, 500,000,000 shares authorized,116,378,064 shares issued and 107,222,530 shares outstanding at June 30, 2016; 113,259,408 shares issued and 107,715,436 shares outstanding at December 31, 2015	1,164				1,133
Additional paid-in capital	353,856				322,492
Accumulated deficit	(355,161		)		(481,773		)
Accumulative other comprehensive loss	(2,732		)		(2,488		)
Treasury stock	(54,646		)		(52,677		)
Total stockholders’ equity (deficit)	(57,519		)		(213,313		)
Total liabilities and stockholders’ equity (deficit)	$	492,931			$	460,289

Table 2
Accretive Health, Inc.
Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share data)
	Three Months Ended June 30,								Six Months Ended June 30,
		2016				2015				2016				2015
	(unaudited)								(unaudited)
Net services revenue	$	8,672			$	22,085			$	360,865			$	33,056
Operating expenses:
Cost of services		45,112				42,762				90,242				84,958
Selling, general and administrative		24,660				20,969				42,196				38,331
Other		8,651				611				19,457				1,886
Total operating expenses		78,423				64,342				151,895				125,175
Income (loss) from operations		(69,751	)			(42,257	)			208,970				(92,119	)
Net interest income		46				69				130				74
Income (loss) before income tax provision		(69,705	)			(42,188	)			209,100				(92,045	)
Income tax provision (benefit)		(28,914	)			(15,900	)			82,488				(35,312	)
Net income (loss)	$	(40,791	)		$	(26,288	)		$	126,612			$	(56,733	)
Net income (loss) per common share:
Basic	$	(0.45	)		$	(0.27	)		$	0.45			$	(0.59	)
Diluted	$	(0.45	)		$	(0.27	)		$	0.45			$	(0.59	)
Weighted average shares used in calculating net income (loss) per common share:
Basic		99,414,066				95,941,077				98,851,934				95,915,255
Diluted		99,414,066				95,941,077				99,951,394				95,915,255
Consolidated statements of comprehensive income (loss)
Net income (loss)		(40,791	)			(26,288	)			126,612				(56,733	)
Other comprehensive loss:
Foreign currency translation adjustments		(304	)			(221	)			(244	)			(273	)
Comprehensive income (loss)	$	(41,095	)		$	(26,509	)		$	126,368			$	(57,006	)

Table 3
Accretive Health, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
	Six Months Ended June 30,
	2016				2015
	(Unaudited)
Operating activities:
Net income (loss)	$	126,612			$	(56,733	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operations:
Depreciation and amortization	4,632				3,818
Share-based compensation	20,413				12,576
Provision/(Recoveries) for doubtful receivables	(27		)		(45		)
Deferred income taxes	82,420				(36,369		)
Excess tax benefits from share-based awards	—				—
Changes in operating assets and liabilities:
Accounts receivable	3,646				1,101
Prepaid income taxes	503				445
Other assets	(3,394		)		(4,472		)
Accounts payable	(1,565		)		(7,540		)
Accrued compensation and benefits	7,213				(2,830		)
Other liabilities	5,079				(2,038		)
Customer liabilities and customer liabilities - related party	(298,064		)		72,904
Net cash provided by (used in) operating activities	(52,532		)		(19,183		)
Investing activities:
Purchases of property, equipment and software	(7,097		)		(8,348		)
Proceeds from maturation of short-term investments	1,023				—
Net cash used in investing activities	(6,074		)		(8,348		)
Financing activities:
Series A convertible preferred stock and warrant issuance, net of issuance costs	178,669				—
Exercise of vested options	88				—
Restricted cash released from letter of credit	—				5,000
Excess tax benefit from share-based awards	—				—
Purchase of treasury stock	(1,969		)		(517		)
Net cash provided by financing activities	176,788				4,483
Effect of exchange rate changes on cash	(6		)		(222		)
Net increase (decrease) in cash and cash equivalents	118,176				(23,270		)
Cash and cash equivalents at beginning of period	103,497				145,167
Cash and cash equivalents at end of period	$	221,673			$	121,897
Supplemental disclosure of non-cash financing activities
Accrued dividends payable to Preferred Stockholders	$	(4,040	)		$	—
Accrued liabilities related to purchases of property, equipment and software	991				—
Accounts payable related to purchases of property, equipment and software	—				5,250

Table 4
Accretive Health, Inc.
Reconciliation of GAAP Revenue to Non-GAAP Gross Cash Generated from Customer Contracting Activities
(In thousands)
	Three Months Ended June 30,										2016 vs. 2015 Change									Six Months Ended June 30,										2016 vs. 2015 Change
		2016				2015					Amount			%							2016				2015					Amount			%
Consolidated Statement of Operations Data:
RCM services: net operating fees	$	2,608			$	9,560					$	(6,952	)		-72.7	%				$	251,309			$	13,170					$	238,139		fav.
RCM services: incentive fees		-				6,105						(6,105	)		-100.0	%					97,999				8,005						89,994		fav.
RCM services: other		2,061				2,958						(897	)		-30.3	%					4,462				4,092						370			9.0	%
Other services fees		4,003				3,462						541			15.6	%					7,095				7,789						(694	)		-8.9	%
Total net services revenue		8,672				22,085						(13,413	)		-60.7	%					360,865				33,056						327,809			fav.
Change in deferred customer billings		29,602				25,133						4,469			17.8	%					(281,737	)			69,060						(350,797	)		fav.
Gross cash generated from customer contracting activities	$	38,274			$	47,218					$	(8,944	)		-18.9	%				$	79,128			$	102,116					$	(22,988	)		-22.5	%
Components of Gross Cash Generated from Customer Contracting Activities:
RCM services: net operating fee	$	23,886			$	27,050					$	(3,164	)		-11.7	%				$	48,690			$	57,239					$	(8,549	)		-14.9	%
RCM services: incentive fee		7,368				14,511						(7,143	)		-49.2	%					16,235				32,642						(16,407	)		-50.3	%
RCM services: other		3,016				2,196						820			37.3	%					7,108				4,447						2,661			59.8	%
Total RCM services fees		34,270				43,757						(9,487	)		-21.7	%					72,033				94,328						(22,295	)		-23.6	%
Other services fees		4,004				3,461						543			15.7	%					7,095				7,788						(693	)		-8.9	%
Gross cash generated from customer contracting activities	$	38,274			$	47,218					$	(8,944	)		-18.9	%				$	79,128			$	102,116					$	(22,988	)		-22.5	%

* fav. - Favorable

unfav. - Unfavorable

Table 5
Accretive Health, Inc.
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Cash Generated from Customer Contracting Activities
(In thousands)
	Three Months Ended June 30,								2016 vs. 2015 Change							Six Months Ended June 30,								2016 vs. 2015 Change
		2016				2015			Amount			%					2016				2015			Amount			%
Net income (loss)	$	(40,791	)		$	(26,288	)		$	(14,503	)		unfav.			$	126,612			$	(56,733	)		$	183,345			fav.
Net interest income		(46	)			(69	)			23			-33.3	%			(130	)			(74	)			(56	)		75.7	%
Income tax provision (benefit)		(28,914	)			(15,900	)			(13,014	)		81.8	%			82,488				(35,312	)			117,800			unfav.
Depreciation and amortization expense		2,361				2,101				260			12.4	%			4,632				3,818				814			21.3	%
Share-based compensation expense		11,785				7,807				3,978			51.0	%			18,683				13,003				5,680			43.7	%
Other		8,651				611				8,040			unfav.				19,457				1,886				17,571			unfav.
Adjusted EBITDA		(46,954	)			(31,738	)			(15,216	)		47.9	%			251,742				(73,412	)			325,154			fav.
Change in deferred customer billings		29,602				25,133				4,469			17.8	%			(281,737	)			69,060				(350,797	)		fav.
Net cash generated from customer contracting activities	$	(17,352	)		$	(6,605	)		$	(10,747	)		unfav.			$	(29,995	)		$	(4,352	)		$	(25,643	)		unfav.

* fav. - Favorable

unfav. - Unfavorable

Table 6
Accretive Health, Inc.
Share-Based Compensation Expense Allocation Details
(In thousands)
	Three Months Ended June 30,								Six Months Ended June 30,
		2016				2015				2016				2015
	(unaudited)								(unaudited)
Cost of services	$	1,520			$	1,204			$	3,523			$	2,604
Selling, general and administrative		10,265				6,603				15,160				10,399
Other		1,828				-				1,828				-
Total share-based compensation expense	$	13,613			$	7,807			$	20,511			$	13,003

Table 7
Accretive Health, Inc.
Depreciation and Amortization Expense Allocation Details
(In thousands)
	Three Months Ended June 30,								Six Months Ended June 30,
		2016				2015				2016				2015
	(unaudited)								(unaudited)
Cost of services	$	2,229			$	1,826			$	4,327			$	3,308
Selling, general and administrative		132				275				305				510
Total depreciation and amortization	$	2,361			$	2,101			$	4,632			$	3,818

Table 8
Accretive Health, Inc.
Condensed Consolidated Non-GAAP Financial Information
(In thousands)
	Three Months Ended June 30,								Six Months Ended June 30,
		2016				2015				2016				2015
GAAP net services revenue	$	8,672			$	22,085			$	360,865			$	33,056
Increase (decrease) in deferred customer billings		29,602				25,133				(281,737	)			69,060
Gross cash generated from customer contracting activities		38,274				47,218				79,128				102,116
Operating Expenses1:
Cost of services		41,363				39,732				82,392				79,046
Selling, general and administrative		14,263				14,091				26,731				27,422
Sub-total		55,626				53,823				109,123				106,468
Net cash generated from customer contracting activities	$	(17,352	)		$	(6,605	)		$	(29,995	)		$	(4,352	)
Net cash generated margin		-45.3	%			-14.0	%			-37.9	%			-4.3	%
1Excludes share-based compensation, depreciation and amortization, and other costs

 

Contact:
Accretive Health, Inc.
Investor and Media Relations:
Atif Rahim
312.324.5476
investorrelations@accretivehealth.com